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Epilepsy and headache are the two most common neu-
rologic disorders affecting individuals of all ages worldwide. 
They constitute an important health and socioeconomic 
problem1,2. Approximately 50 million people suffer from epi-
lepsy3, while in the adult population the prevalence of active 
headache is around 46%2. 
Drug treatment of epilepsy, with antiepileptic drugs, 
and headache, with prophylactic drugs, is prolonged in 
most cases (years to decades). Moreover, although for both 
pathologies it is recommended the use of a single antiepi-
leptic or prophylactic drug, the use of polytherapy is very 
common4-6. Therefore, there is high risk of interactions be-
tween the drugs used for the primary neurologic disorder 
and other ones necessary throughout life for different acute 
or chronic conditions. 
In the treatment of chronic diseases, such as epilepsy and 
migraines, it is important to know the side effects of the pre-
scribed drugs, as well as their contraindications and interac-
tions, since most patients will need at some point to use med-
ications for other associated diseases4-7.
Once they are diseases that affect individuals at any age, 
chronically, comorbidities are common in people with epi-
lepsy and headache and they lead to the use of other medi-
cations, which are added to the primary neurological drugs. 
In subjects with migraine, the second most common type of 
chronic headache, a long list of comorbidities are reported, 
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AbsTRACT
Comorbidities are often associated with chronic neurological diseases, such as headache and epilepsy. Objectives: To identify comorbidities 
associated with epilepsy and headaches, and to determine possible drug interactions. Methods: A standardized questionnaire with informa-
tion about type of epilepsy/headache, medical history, and medication was administered to 80 adult subjects (40 with epilepsy and 40 with 
chronic headache). Results: Patients with epilepsy had an average of two comorbidities and those with headache of three. For both groups, 
hypertension was the most prevalent. On average, patients with epilepsy were taking two antiepileptic medications and those with headache 
were taking only one prophylactic medication. Regarding concomitant medications, patients with epilepsy were in use, on average, of one 
drug and patients with headache of two. Conclusions: Patients with chronic neurological diseases, such as epilepsy and headaches, have 
a high number of comorbidities and they use many medications. This may contribute to poor adherence and interactions between different 
medications.
Key words: epilepsy, headache, drugs interaction.
REsumo
As comorbidades geralmente estão associadas a doenças neurológicas crônicas, tais como cefaleia e epilepsia. Objetivos: Identificar comor-
bidades associadas à epilepsia e cefaleia e determinar as possíveis interações de drogas. Métodos: Questionário padronizado com infor-
mações sobre o tipo de epilepsia/cefaleia, os antecedentes médicos e as medicações foi aplicado a 80 indivíduos adultos (40 com epilepsia 
e 40 com cefaleia crônica). Resultados: Pacientes com epilepsia e cefaleia apresentaram uma média de duas e três comorbidades, respec-
tivamente, sendo, para ambos, hipertensão arterial sistêmica a mais prevalente. Em média, os pacientes com epilepsia estavam em uso de 
duas medicações antiepilépticas; aqueles com cefaleia, uma medicação profilática. Em relação às medicações concomitantes, os pacientes 
com epilepsia estavam em uso, em média, de uma droga e os pacientes com cefaleia de duas. Conclusões: Pacientes com doenças neuroló-
gicas crônicas, como epilepsia e cefaleia, apresentam elevado número de comorbidades e utilizam grande número de medicações. Isso pode 
contribuir para diminuir a aderência ao tratamento e facilitar interações entre diversas medicações.
Palavras-Chave: epilepsia, cefaleia, interações medicamentosas. 
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the most frequent are psychiatric, respiratory, and cardiovas-
cular disorders8. Similarly, a recent study showed that up to 
60% of patients with epilepsy take more than five different 
drugs, compared with 15% of the general population. This in-
creases the likelihood of drug interactions, particularly when 
the antiepileptic medication induces hepatic metabolism, 
leading to a decreased level of other medications4. 
This study aimed at identifying comorbidities associat-
ed with epilepsy and chronic headaches and the frequency 
and type of medications used in order to determine possible 
drugs interactions.
mETHoDs
In this study, we interviewed 80 individuals followed at 
the Neurology Service of Campinas State University. The 
questionnaire consisted of information about the type of 
epilepsy or headache, drugs used to treat the neurological 
disease, current health and medical history, and other con-
comitant medications used. The interviews were conducted 
between August 2, 2010 and December 16, 2010.
Patients were divided into two groups. The first group 
(Group 1) comprised 40 people with epilepsy, who were sub-
mitted to the questionnaire. The second one (Group 2) con-
sisted of 40 patients with chronic headache matched with 
respect to age and sex to the first group. This group was sub-
jected to another questionnaire.
Patients included in this study were 18 years-old or more 
and with intact ability to answer the questionnaires. Patients 
with mental retardation, behavioral disorder or other evi-
dent abnormalities that could compromise the cooperation 
to respond the questionnaires were excluded. For Group 1, 
patients should have an established diagnosis of epilepsy for 
at least one year in the hospital. For Group 2, patients should 
have a diagnosis of headache for at least one year in the stud-
ied department and should not have epilepsy. 
All patients included in this study signed the informed 
consent approved by the Ethics Committee of the Department 
of Neurology of Faculty of Medicine at Universidade Estadual 
de Campinas, Campinas SP, Brazil. 
REsuLTs
Demographic data
We interviewed 80 patients: 22 men and 58 women, with 
ages ranging from 21 to 86 years-old (medium of 48). 
Group 1 was composed by 40 individuals with epilepsy 
(25 women), with ages raging from 21 to 79 years-old (me-
dium of 46). Thirty-five patients were employed, two unem-
ployed, and three retired. 
Group 2 was composed by 40 individuals with chronic 
headache (33 women), with ages ranging from 26 to 86 years-
old (medium of 49). Thirty-eight patients were employed, one 
retiree, and one unemployed. 
In Group 1, 33 patients had the diagnosis of focal epilep-
sies (21 with temporal lobe epilepsy, eigth with extra-tempo-
ral epilepsy, and four with undetermined epilepsies) and six 
had the diagnosis of generalized epilepsy ( four patients with 
juvenile myoclonic epilepsy and two with other types).
In Group 2, 19 patients had the diagnosis of migraine, two 
of tension-type headache, six of mixed headache (association 
of migraine and tension type headache), four of trigeminal 
neuralgia, and six patients had other types of headache (cer-
vicogenic, post-traumatic and cluster headache). 
Neurological disease and medication 
Patients with epilepsy were using an average of two anti-
epileptic drugs (AEDs), ranging from zero to four drugs. The 
most used AED was carbamazepine (25 patients), followed 
by clobazam (13 patients). 
Patients with chronic headache were using an average of 
one prophylactic drug, ranging from zero to three drugs. The 
most used prophylactic drugs were sertraline, fluoxetine, car-
bamazepine, and valproate ( five patients with each of these 
drugs). 
Comorbidities and medication
The health history questionnaire was divided into comor-
bidities and patients’ complaints or symptoms. Nineteen pa-
tients with epilepsy reported other illnesses. The most com-
mon condition was hypertension. They informed an average 
of two comorbidities (ranging from zero to four) and another 
of two complaints or symptoms (ranging from zero to ten), as 
seen in Fig 1 and 2. 
Twenty-two patients with chronic headache reported 
other illnesses. The most common condition was hyperten-
sion. They informed an average of three comorbidities (rang-
ing from zero to seven) and another of two complaints or 
symptoms (ranging from zero to nine), as can also be seen 
in Fig 1 and 2.
Regarding the chronic use of medications related to the 
comorbidities, patients with epilepsy were using an average 
of one drug (ranging from zero to four). The most used was 
levothyroxine, followed by captopril. Considering the amount 
of drugs chronically used (drugs for epilepsy and comorbidi-
ties), 21 patients (52%) were taking two drugs, 16 (40%) were 
taking three or four drugs, and three (8%) were taking five or 
more drugs (Fig 3).
Patients with chronic headache were using an average of 
two drugs (ranging from zero to nine). The most commonly 
used drug was hydrochlorothiazide (six patients), followed by 
captopril ( four patients). Considering the amount of drugs 
used chronically (drugs for headache and comorbidities), 24 
patients (60%) were using medications, six (15%) were taking 
three or four drugs and ten (25%) were taking five or more 
(Fig 3).
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DIsCussIoN
In this study, we verified that patients with epilepsy and 
chronic headache have a large number of other medical con-
ditions and that the frequency of these comorbidities does 
not differ in both groups. We have also observed a large num-
ber of medications used by these patients for both the neuro-
logical disorder and the other diseases. 
The importance of these facts lies in the high incidence 
of such diseases and in the fact that these neurological con-
ditions require treatment for periods, ranging from years to 
decades and sometimes for the entire life. This leads to the 
possibility of poor adherence to the prescribed medication, 
drug interactions, and prejudice of the treatment.
Gidal et al., in a recent study, showed that up to 47% of 
men and 60% of women with epilepsy from 45 to 64 years-
old take more than five drugs chronically, compared with 2% 
of men and 3% of women in the general population4. In this 
study, irrespective of age, 48% of patients with epilepsy and 
40% of those with chronic headache were using three or more 
concomitant drugs. 
Drug adherence is an important problem in chronically 
treated patients. The low adherence may have implications, 
such as inappropriate treatment, increasing of hospitaliza-
tions and even an increase of mortality in patients with epi-
lepsy9. A survey showed that up to 70% of patients with epi-
lepsy report missing doses10. The high number of drugs taken 
may significantly contribute to the decrease of adherence. 
The other problem of concomitant use of many drugs in 
epilepsy patients is that the classical anti-epileptic drugs, 
such as carbamazepine, are known inducers of hepatic me-
tabolism. Those drugs interfere with the effectiveness of 
drugs, such as steroids, warfarin, antibiotics, antipsychotics 
and antidepressants. For example, Oberndorfer et al. found 
a decreased efficacy of chemotherapy CCNU (lomustine) 
in patients receiving AED inducers of metabolism. In this 
study, patients with glioblastoma multiform that were using 
inducers AEDs had significant smaller survival rates than 
those in use of non-inducers AEDs11.
The most used prophylatic medications for chronic head-
ache in the studied patients were inhibitors of serotonin 
reuptake. These drugs are considered relatively safe and have 
low risk of interactions. However, some clinically relevant in-
teractions may occur by inhibition of CYP isoenzymes, espe-
cially when in a regimen of multiple drugs, which is the case 
of our patients12. Serotonin reuptake inhibitors can also cause 
an increase in plasma levels of AEDs through inhibition of 
P450 2D6 isoenzyme13. As the concomitant administration of 
AEDs and serotonin reuptake inhibitors is common, thera-
peutic drug monitoring may be useful in designing correct 
and rational therapy, but further studies are necessary13.
We can conclude by these data that patients with chronic 
neurological diseases, such as epilepsy and headaches, have 
a high number of comorbidities. These individuals are gener-
ally subject to the use of a large number of different medica-
tions, both for the neurological condition or comorbidities. 
This fact may contribute to poor adherence of these pa-
tients, besides being a risk for interactions between different 
medications.
Fig 1. Percentage of patients with epilepsy and chronic 
headache, according to the number of comorbidities.
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Fig 2. Frequency of different comorbidities in patients with 
epilepsy and chronic headache. 
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Fig 3. Percentage of patients with epilepsy and chronic 
headache, according to the number of medications used for 
comorbidities.
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